Association between soy and isoflavone consumption, gastrointestinal (GI) cancer risk
the ONA take:
According to a new study published in the European Journal of Nutrition, soy consumption is only associated with a small decrease in gastrointestinal cancer risk, while isoflavone consumption is significantly associated with a reduction in gastrointestinal cancer risk.
For the study, researchers sought to investigate the association between soy and isoflavone consumption and gastrointestinal cancer risk. Isoflavone is an active soy constituent but can be consumed as a dietary supplement.
Researchers identified 22 case-control and 18 cohort studies with a total participation of 633,476 patients and 13,639 cases of gastrointestinal cancer. Of the 40 studies, 10 were used for a subgroup analysis for isoflavone consumption.
Results showed that there was only a small reduction in gastrointestinal cancer risk due to soy intake (combined odds ratio = 0.93; 95% CI: 0.87 - 0.99; P = 0.01).
Particularly, the association was stronger for colon and colorectal cancers. In contrast, the subgroup analysis for isoflavone showed a significant reduction in gastrointestinal cancer risk, especially colorectal cancer risk, due to isoflavone consumption (OR = 0.73; 95% CI: 0.59 - 0.92; P = 0).
Soy consumption is only associated with a small decrease in gastrointestinal cancer risk.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|